Subcutaneous immunotherapy with depigmented-polymerized allergen extracts: a systematic review and meta-analysis

Abstract

Background Double-blind, placebo-controlled trials (DBPCTs) have confirmed the efficacy of allergen-specific immunotherapy (AIT) with depigmented-polymerized allergen extracts (DPAEs). This systematic review evaluates the efficacy of AIT using different allergens in different severity stages of rhinoconjunctivitis with or without asthma in the pollen studies and asthma and rhinitis in the house dust mite studies in comparison to placebo. Methods We used MEDLINE, Embase, CENTRAL and LILACS databases to review DBPCTs published until July 2016. The combined symptom and medication score (cSMS) served as primary endpoint. The total rhinoconjunctivitis symptom score (RCSS) and total score in Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) were secondary efficacy endpoints. Solicited local and systemic adverse events were secondary safety endpoints. We assumed a random effects model with standardized mean differences (SMDs) or mean differences as summary statistics. In a subgroup analysis, we classified the studies following the GINA (Global Initiative for Asthma) and ARIA (Allergic Rhinitis and its Impact on Asthma) guidelines for rhinoconjunctivitis and asthma severity. Results Six DBPCTs in pollen and 2 trials in house dust mites (HDM) were selected. Patients (N = 915) with intermittent or mild persistent asthma were included in 3 (37.5%) and 5 (62.5%) trials, respectively. Two (25%) HDM studies included patients with moderate persistent asthma, 4 trials patients with moderate-to-severe rhinoconjunctivitis. Treatment periods ranged from 12 to 24 months. AIT with DPAEs yielded significantly lower cSMS (SMD: 1.9, 95% CI: 0.9–2.8) and RQLQ (SMD: 0.3, 95% CI: 0.1–0.5) values than did placebo. An exploratory analysis of cSMS and RCSS suggested that the efficacy of AIT treatment with DPAEs was higher in trials including patients with more severe rhinoconjunctivitis and asthma. A publication bias was not detected. Heterogeneity between individual studies was explained by differences in severity. Patients receiving DPAEs did not experience a significantly higher risk of local (OR: 1.55, 95% CI: 0.86–2.79) or systemic reactions (OR: 1.94, 95% CI: 0.98–3.84). Conclusions Compared to placebo, AIT with DPAEs is effective in patients with pollen- or HDM-induced rhinoconjunctivitis with or without allergic asthma and improves health-related quality of life. It does not differ significantly in safety and tolerability. Electronic supplementary material The online version of this article (10.1186/s13601-019-0268-5) contains supplementary material, which is available to authorized users.

The Impact of Excluding Nonrandomized Studies From Systematic Reviews in Rare Diseases: “The Example of Meta-Analyses Evaluating the Efficacy and Safety of Enzyme Replacement Therapy in Patients With Mucopolysaccharidosis”

“…Accordingly, we found in our study additional systematic reviews in LILACS that were not indexed in other databases (Pal et al, 2015). This was also the case for previous studies performed on MPS and other indications (Pérez-López et al, 2017;Sampayo-Cordero et al, 2018;Sampayo-Cordero et al, 2019;Mösges et al, 2019).…”

Effect of Dermatophagoides pteronyssinus Immunotherapy on Upper and Lower Airway Eosinophilic Inflammatory Response to Nasal Allergen Challenge

“… 26 The efficacy of AIT for AR and/or asthma has been confirmed in recent systematic meta-analyses. 27 28 29 Indeed, subjects receiving AIT in our study exhibited better AR symptoms compared to subjects without AIT as assessed by self-scored questionnaires. NPT is an objective tool to diagnose AR and has been used for evaluating AIT efficacy in clinical trials.…”

A meta‐analysis on allergen‐specific immunotherapy using MCT® (MicroCrystalline Tyrosine)‐adsorbed allergoids in pollen allergic patients suffering from allergic rhinoconjunctivitis

“…In a previous product‐specific analysis by Mösges et al. with polymerized allergen extracts, it was also shown that asthma is not a risk factor when treating patients with AIT 63 …”